Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer

被引:93
作者
Wadelius, M
Autrup, JL
Stubbins, MJ
Andersson, SO
Johansson, JE
Wadelius, C
Wolf, CR
Autrup, H
Rane, A
机构
[1] Univ Uppsala Hosp, Dept Med Sci, S-75185 Uppsala, Sweden
[2] Univ Uppsala Hosp, Dept Genet & Pathol, Clin Genet Unit, Uppsala, Sweden
[3] Univ Aarhus, Steno Ctr Publ Hlth, Aarhus, Denmark
[4] Univ Dundee, Ninewells Hosp, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee, Scotland
[5] Glaxo Wellcome Res & Dev Ltd, GLP Clin Genotyping Grp, Ware, Herts, England
[6] Orebro Med Ctr Hosp, Dept Urol, Orebro, Sweden
来源
PHARMACOGENETICS | 1999年 / 9卷 / 03期
关键词
CYP; GSTP1; NAT2; prostate cancer;
D O I
10.1097/00008571-199906000-00008
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The development of prostate cancer is dependent on heredity, androgenic influences, and exposure to environmental agents. A high intake of dietary fat is associated with an increased risk of prostate cancer, either through influence on steroid hormone profiles or through production of carcinogenic compounds that require biotransformation by enzymes. The polymorphic glutathione S-transferase (GST), N-acetyltransferase (NAT), and cytochrome P450 (CYP) enzymes are of particular interest in prostate cancer susceptibility because of their ability to metabolize both endogenous and exogenous compounds, including dietary constituents. Association between different NAT2, CYP2D6, CYP2C19 and GSTP1 genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals, The combined Swedish and Danish study population was analysed by polymerase chain reaction for the NAT2 alleles *4, *5A, *5B, *5C, *6 and *7, and for the CYP2D6 alleles *1, *3 and *4. The Swedish subjects were;also analysed for the CYP2C19 alleles *1 and *2, and the GSTP1 alleles *A, *B and *C. No association was found between prostate cancer and polymorphisms in NAT2, CYP2D6, CYP2C19 or GSTP1, An association between CYP2D6 poor metabolism and prostate cancer was seen among smoking Danes; odds ratio 3.10 (95% confidence interval 1.07; 8.93), P = 0.03, but not among smoking Swedes; odds ratio 1.19 (95% confidence interval 0.41; 3.42), P = 0.75. Smoking is not a known risk factor for prostate cancer, and the association between CYP2D6 poor metabolism and prostate cancer in Danish smokers may have arisen by chance. Pharmacogenetics 9:333-340 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:333 / 340
页数:8
相关论文
共 41 条
  • [1] Andersson SO, 1996, CANCER EPIDEM BIOMAR, V5, P509
  • [2] Brockmoller J, 1996, CANCER RES, V56, P3915
  • [3] CANCER GENES - SINGLE AND SUSCEPTIBILITY - EXPOSING THE DIFFERENCE
    CAPORASO, N
    GOLDSTEIN, A
    [J]. PHARMACOGENETICS, 1995, 5 (02): : 59 - 63
  • [4] EPIDEMIOLOGIC EVIDENCE REGARDING PREDISPOSING FACTORS TO PROSTATE-CANCER
    CARTER, BS
    CARTER, HB
    ISAACS, JT
    [J]. PROSTATE, 1990, 16 (03) : 187 - 197
  • [5] MENDELIAN INHERITANCE OF FAMILIAL PROSTATE-CANCER
    CARTER, BS
    BEATY, TH
    STEINBERG, GD
    CHILDS, B
    WALSH, PC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) : 3367 - 3371
  • [6] Chen J, 1998, CANCER RES, V58, P3307
  • [7] Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
    Cooney, KA
    McCarthy, JD
    Lange, E
    Huang, L
    Miesfeldt, S
    Montie, JE
    Oesterling, JE
    Sandler, HM
    Lange, K
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (13) : 955 - 959
  • [8] A TOBACCO SMOKE-DERIVED NITROSAMINE, 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE, IS ACTIVATED BY MULTIPLE HUMAN CYTOCHROME P450S INCLUDING THE POLYMORPHIC HUMAN CYTOCHROME P4502D6
    CRESPI, CL
    PENMAN, BW
    GELBOIN, HV
    GONZALEZ, FJ
    [J]. CARCINOGENESIS, 1991, 12 (07) : 1197 - 1201
  • [9] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
  • [10] Feigelson HS, 1996, J CELL BIOCHEM, P15